Adlinda Alip

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 308 citations · Full text

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Yi‐Long Wu, D. Planchard, Shun Lü et al. · Annals of Oncology · 2018 · 291 citations · Full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee et al. · Annals of Oncology · 2020 · 111 citations · Full text

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

B.C. Cho, Enriqueta Felip, Alexander I. Spira et al. · Annals of Oncology · 2023 · 83 citations · Full text

Lba14 Amivantamab, Medicine, Phase Iii +7

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Enriqueta Felip, Byoung Chul Cho, Valentín García‐Gutiérrez et al. · Annals of Oncology · 2024 · 72 citations · Full text